Kyle Greenway
Assistant Professor in Psychiatry at McGill University; attending psychiatrist at the Jewish General Hospital; investigator at the Lady Davis Institute
Key Impact
He is a McGill-based psychiatrist and psychedelic researcher who co-led the ReSPCT guidelines for psychedelic clinical trials and studies ketamine- and psilocybin-assisted therapies.
Background & Research
Kyle T. Greenway, MD, MSc, FRCPC, is an Assistant Professor in Psychiatry at McGill University, a staff psychiatrist at the Jewish General Hospital, and an investigator at the Lady Davis Institute. His research focuses on novel psychiatric interventions, especially psychedelic-assisted psychotherapies, ketamine-assisted therapy, and the role of extra-pharmacological factors such as set and setting in treatment outcomes. He also directs the Jewish General Hospital’s ketamine-assisted therapy program and has trained at Imperial College’s Psychedelic Research Centre.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →